VLON   $12.000001  -12.68% Market Closed

Vallon Pharmaceuticals Inc
Last Events:

2023-03-30 Trend pattern changed from канал to сужающийся канал.

2023-03-30 Signal in Stochastic changed from bullish reversal to bearish recovery. The stochastic indicator is in the oversold territory and it falls. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: main and signal line crossing.

2023-03-30 Signal in MACD changed from bullish weakening to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: signal line crossed the middle level.

2023-03-30 Signal in RSI changed from bullish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: exit from the overbought zone.

2023-03-30 Signal in EMA50 changed from bullish reversal to bearish reversal. 2023-03-17 the price crossed down the moving average line and formed a short-term downside trend.

2023-03-30 Signal in EMA20 changed from bullish reversal to bearish reversal. 2023-03-17 the price crossed down the moving average line and demonstrates a strong downside trend.

2023-03-30 Trend Power changed from strong to almost flat.

2023-03-30 Trend changed from down and flat to turning up.


Current temperature: 2.79
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd - - -
stoch - - -
ma20 - Sell Sell
ma50 - - -
ma100 Sell Sell Sell
Candlestick PatternNov. 4, 2022 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US92023M1018
ceo Mr. David C. Baker
Website https://www.vallon-pharma.com
As of April 21, 2023, Vallon Pharmaceuticals, Inc. was acquired by GRI Bio, Inc., in a reverse merger transaction. Vallon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. The company's lead investigational product candidate is ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania.